The focus of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Prostate Cancer (PC) Program is the development of new approaches to prostate cancer detection, diagnosis and treatment. The Program emphasizes a comprehensive basic and translational research approach to prostate cancer, embodied in three interactive Program scientific goals: 1) understanding the molecular genetics and epidemiology of prostate cancer, 2) elucidating the molecular underpinnings of prostate cancer, and 3) discovering and developing new prostate cancer therapies. Through advances in each of these goals, the Program has translated several discoveries into high-impact preclinical and clinical studies. The PC Program includes 30 Program members from four departments at the Johns Hopkins University School of Medicine (Oncology, Pathology, Radiation Oncology and Molecular Radiation Sciences, and Urology) and one from Howard University. The Program also closely interacts with the Cancer Immunology Program, the Cancer Molecular and Functional Imaging Program, and the Cancer Prevention and Control Program at the Johns Hopkins Bloomberg School of Public Health (Epidemiology). The research portfolio of the Program, which encompasses nearly all prostate cancer research at Johns Hopkins, receives support from the National Cancer Institute and other peer-reviewed funding sources, including a Prostate Cancer SPORE. The Program members have funding of $20.3 million total costs annually, of which $13.8 million total costs is peer-reviewed. Twenty-one Program members (70%) have peer-reviewed funding. Program trainees, both pre- and Postdoctoral, are supported by training grants from the SKCCC, the Department of Pharmacology and Molecular Sciences, and the Cellular and Molecular Medicine Program. Collectively, the PC Program membership has published 599 publications. The Program is highly interactive, with 245 (41%) Intra-Programmatic, 219 (37%) Inter-Programmatic and 238 (40%) multi-institutional collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-55
Application #
9519890
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
55
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225

Showing the most recent 10 out of 2393 publications